Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission

close

Get every new post delivered right to your inbox.

Original Source